Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease

被引：21

作者：

Kimura, M ^{[1
]}

Asada, T

Uno, M

Machida, N

Kasuya, K

Taniguchi, Y

Fujita, T

Nishiyama, E

Iwamoto, N

Arai, H

机构：

[1] Natl Ctr Hosp Mental Nervous & Muscular Disorders, NCNP, Dept Psychiat, Tokyo, Japan

[2] Mitsubishi Kagaku Bioclin Labs Inc, Dept Res & Dev, Tokyo, Japan

[3] Oriental Yeast Co Ltd, Osaka Biochem Plant, Tokyo, Japan

[4] Oriental Yeast Co Ltd, Nagahama Inst Biochem Sci, Tokyo, Japan

[5] Juntendo Univ, Sch Med, Dept Psychiat, Bunkyo Ku, Tokyo 1138421, Japan

来源：

NEUROSCIENCE LETTERS | 1999年 / 273卷 / 02期

关键词：

Alzheimer's disease; amyloid P component; cerebrospinal fluid; Mini-Mental State Examination; Tau protein; soluble amyloid precursor protein;

D O I：

10.1016/S0304-3940(99)00631-X

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Serum amyloid P component (SAP) is a normal plasma constituent that is observed both in senile plaque and in neurofibrillary tangle in brains of patients with Alzheimer's disease (AD). In this study, we evaluated the SAP levels in cerebrospinal fluid (CSF) of 72 patients with AD, 11 frontotemporal dementia and nine normal control subjects. There was no significant difference in the SAP levels between the AD group and other groups. However, among AD patients, cognitive function was rated using the Mini-Mental State Examination and was correlated with the SAP level (R = 0.38, P < 0.05). Our results suggest that measurement of the SAP levels in CSF can be useful for assessing the degree of cognitive impairment in AD patients. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：137 / 139

页数：3

共 16 条

[1] TAU IN CEREBROSPINAL-FLUID - A POTENTIAL DIAGNOSTIC MARKER IN ALZHEIMERS-DISEASE [J].

ARAI, H ;

TERAJIMA, M ;

MIURA, L ;

HIGUCHI, S ;

MURAMATSU, T ;

MACHIDA, N ;

SEIKI, H ;

TAKASE, S ;

CLARK, CM ;

LEE, VMY ;

TROJANOWSKI, JQ ;

SASAKI, H .

ANNALS OF NEUROLOGY, 1995, 38 (04) :649-652

[2]

BRUN A, 1994, J NEUROL NEUROSUR PS, V57, P416

[3]

CORIA F, 1988, LAB INVEST, V58, P454

[4] IMMUNODETECTION OF THE AMYLOID-P COMPONENT IN ALZHEIMERS-DISEASE [J].

DUONG, T ;

POMMIER, EC ;

SCHEIBEL, AB .

ACTA NEUROPATHOLOGICA, 1989, 78 (04) :429-437

[5] AMYLOID-P COMPONENT PROMOTES AGGREGATION OF ALZHEIMERS BETA-AMYLOID PEPTIDE [J].

HAMAZAKI, H .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 211 (02) :349-353

[6] CONCENTRATION OF SERUM AMYLOID-P COMPONENT IN THE CSF AS A POSSIBLE MARKER OF CEREBRAL AMYLOID DEPOSITS IN ALZHEIMERS-DISEASE [J].

HAWKINS, PN ;

ROSSOR, MN ;

GALLIMORE, JR ;

MILLER, B ;

MOORE, EG ;

PEPYS, MB .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 201 (02) :722-726

[7]

HIXON JE, 1990, J LIPID RES, V31, P545

[8]

KALARIA RN, 1991, ANN NY ACAD SCI, V640, P145

[9]

KIMURA M, 1994, J NEUROL, V241, P170

[10] DECREASED ALPHA-SECRETASE-CLEAVED AMYLOID PRECURSOR PROTEIN AS A DIAGNOSTIC MARKER FOR ALZHEIMERS-DISEASE [J].

LANNFELT, L ;

BASUN, H ;

WAHLUND, LO ;

ROWE, BA ;

WAGNER, SL .

NATURE MEDICINE, 1995, 1 (08) :829-832

← 1 2 →